These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 24206430

  • 1. Abatacept in B7-1-positive proteinuric kidney disease.
    Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW, Mundel P.
    N Engl J Med; 2013 Dec 19; 369(25):2416-23. PubMed ID: 24206430
    [Abstract] [Full Text] [Related]

  • 2. Podocyte-Targeted Treatment for Proteinuric Kidney Disease.
    Mundel P.
    Semin Nephrol; 2016 Nov 19; 36(6):459-462. PubMed ID: 27987545
    [No Abstract] [Full Text] [Related]

  • 3. Benefit of B7-1 staining and abatacept for treatment-resistant post-transplant focal segmental glomerulosclerosis in a predominantly pediatric cohort: time for a reappraisal.
    Burke GW, Chandar J, Sageshima J, Ortigosa-Goggins M, Amarapurkar P, Mitrofanova A, Defreitas MJ, Katsoufis CP, Seeherunvong W, Centeno A, Pagan J, Mendez-Castaner LA, Mattiazzi AD, Kupin WL, Guerra G, Chen LJ, Morsi M, Figueiro JMG, Vianna R, Abitbol CL, Roth D, Fornoni A, Ruiz P, Ciancio G, Garin EH.
    Pediatr Nephrol; 2023 Jan 19; 38(1):145-159. PubMed ID: 35507150
    [Abstract] [Full Text] [Related]

  • 4. Abatacept in B7-1-positive proteinuric kidney disease.
    Alachkar N, Carter-Monroe N, Reiser J.
    N Engl J Med; 2014 Mar 27; 370(13):1263-4. PubMed ID: 24670180
    [No Abstract] [Full Text] [Related]

  • 5. Abatacept in B7-1-positive proteinuric kidney disease.
    Benigni A, Gagliardini E, Remuzzi G.
    N Engl J Med; 2014 Mar 27; 370(13):1261-3. PubMed ID: 24670179
    [No Abstract] [Full Text] [Related]

  • 6. Abatacept in B7-1-positive proteinuric kidney disease.
    Greka A, Weins A, Mundel P.
    N Engl J Med; 2014 Mar 27; 370(13):1263-6. PubMed ID: 24670178
    [Abstract] [Full Text] [Related]

  • 7. The role of B7-1 in proteinuria of glomerular origin.
    Novelli R, Benigni A, Remuzzi G.
    Nat Rev Nephrol; 2018 Sep 27; 14(9):589-596. PubMed ID: 29959373
    [Abstract] [Full Text] [Related]

  • 8. A new era of podocyte-targeted therapy for proteinuric kidney disease.
    Haraldsson B.
    N Engl J Med; 2013 Dec 19; 369(25):2453-4. PubMed ID: 24206429
    [No Abstract] [Full Text] [Related]

  • 9. Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down.
    Trimarchi H.
    Recent Pat Endocr Metab Immune Drug Discov; 2015 Dec 19; 9(1):2-14. PubMed ID: 25733062
    [Abstract] [Full Text] [Related]

  • 10. B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS.
    Delville M, Baye E, Durrbach A, Audard V, Kofman T, Braun L, Olagne J, Nguyen C, Deschênes G, Moulin B, Delahousse M, Kesler-Roussey G, Beaudreuil S, Martinez F, Rabant M, Grimbert P, Gallazzini M, Terzi F, Legendre C, Canaud G.
    J Am Soc Nephrol; 2016 Aug 19; 27(8):2520-7. PubMed ID: 26701979
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies
.
    Hansrivijit P, Puthenpura MM, Ghahramani N.
    Clin Nephrol; 2020 Sep 19; 94(3):117-126. PubMed ID: 32589135
    [Abstract] [Full Text] [Related]

  • 12. Successful Treatment With Abatacept in Recurrent Focal Segmental Glomerulosclerosis After Kidney Transplant.
    Shah Y, Almeshari K, Aleid H, Broering D, Alahmadi I, Ali T.
    Exp Clin Transplant; 2019 Jan 19; 17(Suppl 1):178-180. PubMed ID: 30777550
    [Abstract] [Full Text] [Related]

  • 13. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.
    Garin EH, Reiser J, Cara-Fuentes G, Wei C, Matar D, Wang H, Alachkar N, Johnson RJ.
    Pediatr Nephrol; 2015 Mar 19; 30(3):469-77. PubMed ID: 25239302
    [Abstract] [Full Text] [Related]

  • 14. The costimulatory receptor B7-1 is not induced in injured podocytes.
    Baye E, Gallazzini M, Delville M, Legendre C, Terzi F, Canaud G.
    Kidney Int; 2016 Nov 19; 90(5):1037-1044. PubMed ID: 27528551
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
    Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G.
    Am J Physiol Renal Physiol; 2016 Mar 01; 310(5):F335-41. PubMed ID: 26697986
    [Abstract] [Full Text] [Related]

  • 17. Podocyte Expression of B7-1/CD80: Is it a Reliable Biomarker for the Treatment of Proteinuric Kidney Diseases with Abatacept?
    Salant DJ.
    J Am Soc Nephrol; 2016 Apr 01; 27(4):963-5. PubMed ID: 26400567
    [No Abstract] [Full Text] [Related]

  • 18. CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.
    Bassi R, Fornoni A, Doria A, Fiorina P.
    Diabetologia; 2016 Jan 01; 59(1):21-29. PubMed ID: 26409459
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.
    Herrera M, Söderberg M, Sabirsh A, Valastro B, Mölne J, Santamaria B, Valverde AM, Guionaud S, Heasman S, Bigley A, Jermutus L, Rondinone C, Coghlan M, Baker D, Quinn CM.
    Am J Physiol Renal Physiol; 2017 Apr 01; 312(4):F748-F759. PubMed ID: 27440778
    [Abstract] [Full Text] [Related]

  • 20. Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse.
    Cara-Fuentes G, Venkatareddy M, Verma R, Segarra A, Cleuren AC, Martínez-Ramos A, Johnson RJ, Garg P.
    Pediatr Nephrol; 2020 Oct 01; 35(10):1887-1896. PubMed ID: 32399663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.